Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
Eli Lilly and Company LLY announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed ...
The guidelines are part of a national trend by municipal governments and private firms struggling to manage ballooning costs ...
The new generation of weight-loss drugs were initially developed to treat diabetes and work by mimicking a hormone that ...
As the Biden administration is proposing drugs like Ozempic and Wegovy be covered by Medicare and Medicaid, Black people need ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
People taking the weight loss drug Zepbound experienced dramatically greater weight loss than competitor Wegovy in the first head-to-head trial.
Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% ...
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...
That’s according to the latest data from real-time ad trackers iSpot.TV. Their analysts found AbbVie’s immunology drug duo ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...